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CAP, HCS and urinary estriol measurements in risk pregnancies
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Gunnar Ryden, Bertil Kagedal
Department of Obstetricsand Gynecology (G.R.), Department of Clinical Chemistry
(B .K.), University Hospital, Linköping, Sweden
In recent years many different methods have been
published for evaluating the feto-placental unit
which per se indicate that at present no test fulfil
the qualifications of being a suitable test for that
purpose. Among the feto-placental function tests
which have been studied, measurements of urinary
estriol excretion, estimations of human chorionic
somatomammotrophin (HCS) and cystine amino-
peptidase (CAP) in maternal plasma at present
seem to be the most widely used methods. Urinary
estriol assays are generally accepted äs an advisable
method in monitoring the feto-placental unit during
the last trimester. Concerning the clinical signifi-
cance of HCS and CAP assays the opinions are
however more varying. It seemed therefore
desirable to compare the value of all three methods
for evaluating the feto-placental function during
the last trimester. The issue of the study was to
examine if HCS and CAP assays are comparable to
estriol assays in predicting the condition of the
infant at birth and to study if a combination of
tests might give more accurate Information concern-
ing the feto-placental unit than only one test.
l Material
l .1 Normal pregnancy (reference group)
Only healthy women with uncomplicated preg-
nancies who subsequently gave birth to healthy
single infants weighing more than 2500 grams were
included. They were followed by serial sampling
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usually every second week from between the 28 th
to 32nd week of pregnancy until delivery. The
total number of patients in this group was 45.
In order to study the day-to-day Variation, two
samples were taken with 24 hours intervals in a
number of patients, totally 61 duplicate samples.
v
1.2 High risk pregnancy /
The study has been performed during the time
period 1. 1. 1973 to 31. 12. 1974. During this
period the total number of deliveries was 4343,
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with a perinatal mortality of 1.4%. The material
studied, consists of 656 women which were judged
s risk-pregnancies. In these patients one or more
analyses of all three parameters have been per-
formed from the 36 week of pregnancy. Usually
one to two assays have been performed each week.
In some risk pregnancies daily estriol assays have
been performed on clinical indications but only
those assays have been included in the study where
HCS and CAP estimations have been performed
simultaneously. Patients with Rh-immunization
and twin pregnancies have been excluded from the
material. The material has been divided into two
groups.
Normal infant group (540 patients): Pregnancy
with no fetal complications at delivery. APGAR
score > 7 one minute after delivery. Normal birth
weight.
Distressed infant group (116 patients): Pregnancy













A. Cardiotocographic recordings indicating fetal
distress during delivery and APGAR score < 7
one minute after delivery (21 patients).
B. Pregnancy operatively terminated due to fetal
distress (60 patients of which 37 were delivered
by cesarean section and 23 by vacuum extrac-
tion).
C. Birth weight < 2 S.D. from the mean according
to gestational age (35 patients).
2 Methods
Daily urinary Output of estrogens were measured
according to HAINSWORTH and HALL [8]. The
determinations were performed on a TECHNICON
autoanalyzer. Cystine aminopeptidase (CAP) in
serum was measured at 37 °C with the method
described by PEETERS [16] using 1-cystine-bis-para-
nitroanilide s Substrate. Human chorionic somato-
mammotrophin (HCS) was measured according to
LINDBERG et al [12] with use of the Phadebas HCS
Kit from PHARMACIA Diagnostics.
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Fig. 1. Urinary excretion of estriol in 45 normal pregnancies. Each woman collected urin every second week until
delivery. Solid lines are 5-, 50- and 95- percentiles. Dotted lines corresponds to the reference levels used. Results are
given both s mg/24 h and μπιοΙ/24 h.
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Fig. 2. Serum concentration of cystine aminopeptidase, CAP, in 45 normal pregnancies. Samples were taken at 2 weeks
interval. Solid lines are 5-, 50- and 95- percentiles. Dotted line gives the reference level used. Results are giveri b th s
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Fig. 3. Serum concentration of human chorionic somatomammotrophin (HCS) in 45 normal pregnancies. Samples were
taken every second week until delivery. Values above 8 mg/1 are given s 8 mg/1. Solid lines are 5-, 50- and 95- percentiles.
Dotted line gives the reference level used.
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Low biochemical parameters have been defined s
follows:
HCS < 4 mg/1 serum from 36 week of pregnancy
CAP < 80 nkat/1 (4.8 U/l) serum from 36 week of
pregnancy
Urinary estriol excretion
< 70 jumol (20 mg)/24 hours during week 36-37
< 84 μηιοί (24 mg)/24 hours from 38 week of
pregnancy
3 Results
3.1 Normal pregnancy (reference group)
The results obtained in serial samples during normal
pregnancies from the 28th week of pregnancy are
seen in Fig. 1—3.
The day-to-day Variation calculated s the coeffi-
cient of Variation was for CAP assays 8.5%, for
HCS assays 7.3% and for estriol assays 16.0%.
3.2 High risk pregnancy
The frequency of low biochemical parameters in
the normal and distressed infant group are pre-
sented in Tab. I. A statistical analysis using
FISHER'S exact test [2] demonstrates that all three
parameters are valuable in predicting fetal complic-
ations in risk pregnancies. Estriol assays seem to be
somewhat superior to CAP and HCS in this respect,
the differenceishowevernot statistically signiflcant.
Tab. I. The incidence of low biochemical parameters in
the normal and in the distressed infant group.
Tab. II. The incidence of low biochemical levels with two























In order to study if combination of tests give more
Information than only oneparameter the frequency
of low biochemical parameters in the normal and
the infant complication group with different com-




































Normal infant group (93patients)
CAP
estriol




Fig. 4. The distribution of low biochemical values among
540 patients in the normal infant group and among 116
patients in the infant complication group.
culated. Provided that at least one biochemical
Parameter should be low, the results obtained are
shown in Tab. II.
The value of different combinations of the bio-
chemical test is also demonstrated in Fig. 4. Estriol
combined either with CAP or HCS add further 26
patients with low values in the normal infant group
(540 patients) whereas in the complication group
(116 patients) the addition of CAP and HCS predict
12 and 9 new cases respectively.
A statistical analysis was performed using FISHER'S
exact test in order to evaluate if estriol assays
combined either with HCS or CAP gave more In-
formation than only estriol assays. The results
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obtained showed that estriol combined with CAP
gave a significant increase in the number of detected
distressed infants (P = 0.003). Similar results were
also found concerning HCS combined with estriol
comparedto estriol assays (P = 0.04). A combination
of all three tests did not significantly increase the
number of detected risk deliveries compared to the
combination estriol - CAP or estriol - HCS. Ac-
cording to the results obtained, a combination of
the serum assays CAP — HCS predicted the same
incidence of distressed infants äs urinary estriol
assays alone.
4 Discussion and conclusion
A number of studies have repeatedly confirmed
that the quantity of maternal estriol excretion in
urine is a reliable index of the function of the feto-
placental unit. The method has however some
disadvantages, mainly the inaccuracy of the 24
hours sampling. Even with careful urine collection
the individual day-to-day Variation is rather
pronounced (the coefficient of variations was 16%
in the present study). Many reports also indicate
that estriol assays not always reflect the condition
of the feto-placental unit [6, 15, 19], and much
research has during the last decade been directed
towards new methods for evaluating the feto-
placental unit.
In recent years much attention has been directed
towards the determination of HCS äs a possible
mean of monitoring the placental function [1,11,
13, 20, 21]. Among the numerous studies on this
subject a recently published paper by SPELLACY
et al. [21] is the most convincing concerning the
clinical value of HCS-assays. In a large randomized
controlled prospective study they demonstrated
the usefulness of routine prenatal HCS measure-
ments in the management of high risk pregnancies.
They obtained a significantly reduced fetal death
rate in the group controlled by HCS assays com-
pared with a control group.
Concerning CAP assays the results are more con-
flicting. WATSON et al. [23], who compared the
usefulness of CAP, HCS, heat-stable alkaline phos-
phatase (HSAP) and, 17-j3-estradipl in plasma and
urinary estriol excretion found HSAP and CAP to
be the least sensitive indicators of feto-placental
dysfunction in twelve patients studied. In eightof
these patients, however, only mild feto-placental
dysfunction was present, ähd it is therefore diffi-
cult to evaluate their results. CURZEN and VARMA
[7] who compared CAP and urinary estriol assays
concluded that CAP was of no value in predicting
the condition of the feto-placental unit. Other
authors [3, 4, 9, 17, 19, 22] have found that CAP
assays are justified äs a valuable test alongside
estimation of estriol excretion in judging the feto-
placental unit during the last trimester. The various
results obtained by different authors, can partly
be explained by varying assay procedures for CAP.
Especially studies performed using l-cystine-di-ß-
naphtylamide äs Substrate might give different
results depending on the assay procedure [18],
Most of the previous studies have also been perfor-
med on small clinical materials and without a
statistical analysis of the results.
The limits chosen for normal and low values
concerning the different chemical tests might also
influence the results obtained by different authors.
Regarding HCS, most previous authors have used
values of HCS less than 4 mg/1 äs an indication of
decreased placental function and it seemed therefore
reasonable to use the same limit in the present
study. Concerning CAP and estriol assays a statisti-
cal analysis of the results obtained in the reference
group demonstrated that the figures were not
normally distributed. The limit for normal values
regarding CAP and estriol was therefore chosen
corresponding to the 95 percentile in the reference
group. In that way about the same number of low
values was obtained in the normal infänt group for
all three methods studied (Tab. I).
Comparative studies using all three parameters are
scanty. KRISTENSEN et al. [5] compared HCS, CAP
and urinary estriol excretion in pregnancies
complicated with essential hypertension and
preeclampsia. They concluded that a combination
of all three tests contribute to ,a more reliable In-
formation in pregnancies complicated with pre-
eclampsia. The present study confirms that all three
tests are valuable in predicting the condition of the
feto-placental unit in risk pregnancies. When com-
paring all three methods it seems that estriol assays
are somewhat better than HCS and CAP assays in
predicting the condition of the infänt at birth, the
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difference is however not statistically significant.
Nevertheless it must be emphasized that estriol
assays which reflect the condition of the whole
feto-placental unit cannot be substituted by HCS
or CAP assays which only reflect the condition of
the placenta. If estriol assays are combined with
CAP or HCS assays a somewhat better reliability
is obtained. The same conclusions have recently
been made by SCHMID [20] comparing estriol and
estriol-HCS assays.
Urinary estriol assays seem to give the most reliable
Information concerning the condition of the fetus
among the methods used in the present study.
Estriol assays are however inconvenient to use äs a
screening procedure for detecting risk pregnancies,
partly because of the practical problems with the
urine sampling, partly because of the large day-to-
day Variation. The flrst problem can be overcome
with plasma estriol assays. It is however still
questionable if plasma assays of estriol is more
reliable than urinary assays [10,14]. HCS and CAP
assays are more suitable for routine use in large
scale and if they are used simultaneously at least
the same number of distressed fetuses will be
detected äs with estriol assays, HCS and CAP
estimations are very easy to perform and need
only a venous blood sample which can be taken on
out-patient clinics and CAP-assays need rather
ordinary equipment. Even if both tests are reflecting
the condition of the placenta it seems preferable
to use them simultaneously äs they are overlapping
each other to a rather small extent, which may
indicate that they are reflecting different parts of
the placental function. As CAP and HCS only
assess the conditions of the placenta the risk preg-
nancies detected in this way should thereafter be
controlled using more sensitive indicators of fetal
well-being, i.e. estriol assays, ultrasound meas-
urements of the biparietal diameter and cardio-
tocographic recordings in order to estimate the
optimal time for delivery. Management of preg-
nancies in this way might decrease the perinatal
mortality further, especially the number of pre-
natal deaths which at present are responsible for a
large part of the perinatal deaths in füll term preg-
nancies.
Summary
Cystine aminopeptidase (CAP) and human chorionic
somatomammotrophin (HCS) activity in maternal serum
and urinary estriol excretion have been followed simulta-
neously in normal and risk-pregnandes to study if CAP
and HCS are comparable to estriol assays in predicting the
condition of the fetus at birth and to study if a combination
of tests give more accurate Information concerning the
fetoplacental unit than only one test. The results were äs
follows:
Normal pregnancy
The material consists of 45 patients which were followed
every second week from the 28-32 week of pregnancy
until term with serial assays of CAP, HCS and urinary
estriol. (Fig. 1-3).
The coefficient of Variation was for CAP 8,5 per cent, for
HCS 7.3 per cent and for urinary estriol 16.0 per cent.
High-risk-pregnancy
The material has been divided into two groups, a normal
infant group consisting of 540 patients and a distressed
infant group consisting of 116 patients.
Low biochemical parameters have been defined äs follows:
HCS < 4 mg/1 serum from 36 week of pregnancy, CAP <
80 nkat/1 (4.8 U/l) serum from 36 week of pregnancy,
urinary estriol excretion < 70 (20 mg)/24 hours
week 36-37 and < 84 (24 mg)/24 hours from 38
week of pregnancy.
The frequency of low biochemical parameters in the nor-
mal infant group was 8.7% for estriol, 5.4% for CAP and
5.6% for HCS assays. The corresponding figures in the
distressed infant group was 30, 23 and 18% respectively.
The frequency of low biochemical parameters in the
normal and the infant complication group with different
combinations of tests has also been calculated. The results
obtained demonstrated that estriol combined either with
CAP or HCS gave a significant increase in the capacity to
predict fetal complications compared to estriol assays
alone. A combination of all three tests did not significantly
increasethenumberof detected distressed fetuses compared
to a combination of two parameters.
The following conclusions can be made:
All three methods are valuable in predicting fetal compli-
cations. Estriol assays seem to be somewhat superior to
CAP and HCS in this respect. Urinary estriol assays should
be used äs the primary biochemical test for evaluating the
feto-placental unit. If estriol assays are combined with
CAP or HCS an increase in the number of detected distressed
fetuses was obtained compared to estriol assays alone. If
CAP was combined with HCS this combination was at
least äs informative äs estriol assays alone, and this combi-
nation should preferably beused äs screening-test to detect
pregnancies where placental insufficiency may occur.
Keywords: Cystine aminopeptidase, fetal distress, human chorionic somatomammotrophin, placental function test,
risk pregnancy, urinary estriol excretion.
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Zusammenfassung
CAP, HCS and östriolbestimmungen im Urin bei Risiko-
schwangerschaften - Eine vergleichende Studie.
Die mütterlichen Serumaktivitäten der Cystinaminopep-
tidase (CAP) und des menschlichen Chorionsomato-
mammotrophin (HCS) sowie die Östriolausscheidungen
im Urin wurden bei normalen und Risikoschwangerschaf-
ten simultan gemessen. Ziel der Studie war es zu unter-
suchen, ob CAP und HCS mit den Östriolanalysen ver-
gleichbar sind hinsichtlich der Vorhersage des Zustandes
des Feten bei der Geburt; weiter sollte untersucht werden,
ob eine Kombination der Teste eine genauere Information
über die fetoplazentare Einheit vermittelt als ein Test
alleine. Folgende Resultate wurden erzielt.
Normale Schwangerschaft
Das Krankengut bestand aus 55 Patientinnen. Bei diesen
wurde jede zweite Woche, beginnend von der 28.-S2.
Woche der Schwangerschaft bis zum Termin, Serienunter-
suchungen von CAP, HCS und Urinöstriol durchgeführt
(Fig. 1-3). Der Variationskoeffizient für CAP betrug
8.5%, für HCS 7.3% und für das Urinöstriol 16.0%.
» \
Risikoschwangerschaft
Das Krankengut wurde in zwei Gruppen aufgeteilt, eine
Gruppe von 540 Patientinnen mit gesundem Kind und
eine Gruppe von 116 Patientinnen mit beeinträchtigten
Neugeborenen.
Die tiefen biochemischen Parameter wurden folgender-
maßen definiert: HCS < 4 mg/1 Serum für die 36. Schwan-
gerschaftswoche, CAP < 80 nkat/1 im Serum für die 36.
Schwangerschaftswoche und Urinöstriol < 70 /24
Std. für die 36.-37. Woche und < 84 /24 Std. ab der
38. Schwangerschaftswoche.
Die Häufigkeit tiefer bk>chemifeher Parameter betrug in
der normalen Gruppe 8.7% für die Östriolbestimmungen,
5.4% für die CAP-Aktivität und 5.6% für die HCS-Spiegel.
Die korrespondierenden Zahlen für Kinder mit distress
betrugen 30, 23 und 18%. Es wurde auch die Häufigkeit
des Auftretens von tiefen biochemischen Meßwerten in
der Vergleich$gruppe und in der Gruppe mit kindlichen
Komplikationen berechnet beim Vorliegen verschiedener
Kombinationen an Testen. Die erzielten Resultate zeigen,
daß die Östriolbestimmung in Verbindung mit CAP oder
HCS einen signifikanten Zuwachs in Hinblick auf das Vor-
hersagevermögen fetaler Komplikationen mit sich bringt
im Vergleich zu der Östriolbestimmung alleine. Eine Kom-
bination aller drei Teste ließ die Anzahl der Feten mit er-
kanntem distress nicht signifikant ansteigen im Vergleich
zu einer Kombination von nur zwei Meßgrößen.
Die folgenden Schlüsse können gezogen werden:
Alle drei Methoden eignen sich für die Vorhersage fetaler
Komplikationen. Die Östriolbestimmung scheint diesbe-
züglich gewisse Vorteile vor der CAP und HCS-Bestim-
mung zu haben. Die Urinöstriolbestimmungen sollten
daher als erster biochemischer Test verwandt werden, um
die Funktion der fetoplazentaren Einheit zu prüfen. Wenn
die Östriolbestimmung mit der CAP und HCS-Bestimmung
kombiniert wird, ist im Vergleich zur Verwendung der
Östriolbestimmung alleine eine Zunahme der Anzahl
richtig erkannter fetaler Notsituationen gegeben. Wird die
CAP-Bestimmung mit der HCS-Analyse kombiniert, so ist
diese Verbindung zumindest ebenso informativ wie die
Östriolbestimmung alleine; diese Kombination sollte daher
vorzugsweise als screening-Test eingesetzt werden, um
Schwangerschaften zu diagnostizieren, bei denen eine
Plazentainsuffizienz auftreten kann.
Schlüsselwörter: Cystinaminopeptidase, fetaler Distress, menschliches Chorion somatomammotrophin, Placentafunk-
tionstest, Risiko Schwangerschaft, Urinöstriolausscheidung.
Resume
Les mesures de CAP, HCS et d'oestriol urinaire dans les
grossesses a risque - Une etude comparee
Nous avons procede a l'observation simultanee dans des
grossesses normales et ä risque de la «cystine aminopep-
tidase» (CAP) et de l'activite de somato-mammotrophine
chorionique humaine (HCS) dans le serum maternel et
l'excretion d'oestriol urinaire afin d'etudier si la CAP et
la HCS peuvent servir, au meine titre que les tests d'oestriol,
a prediagnostiquer l'etat du foetus a la naissance et si
l'application combinee deplusieurs tests fournit davantage
d'indications sur l'unite foeto-placentaire que le recours ä
un seul test. Nos etudes ä ce sujet ont donne les resultats
suivants:
Grossesse normale
Le materiel concerne 45 parturientes qui ont ete suivies
toutes les deux semaines entre la 28-32eme semaine de
la grossesse et le terme par des series de tests de CAP, HCS
et oestriol urinaire (Fig. l -3).
Le coefficient de Variation a ete de 8,5 % pour la CAP,
de 7,3 % pour la HCS et de 16,0% pour l'oestriol urinaire.
Grossesse a risque eleve
Le materiel a ete divise en deux groupes, un groupe
infantile normal de 540 patients et un groupe infantile
dyspno'ique de 116 patients.
Les parametres biochimiques bas ont ete definis comme
suit: HCS < 4 mg/1 de serum de lä 36eme semaine de
grossesse, CAP < 80 nkat/1 (4,8 U/l) de serum de la
36eme semaine de grossesse, Excretion d'oestriol urinaire
< 70 (20 mg)/24 heures semaine 36-37 et <
84 (24 mg)/24 heures 38eme semaine de grossesse.
La frequence des parametres biochimiques bas dans le
groupe infantile normal a ete de 8,7% pour Foestriol, de
5,4% pour la CAP et de 5,6% pour la HCS. Les courbes
correspondantes du groupe infantile dyspno'ique ont ete
respectivement de 30, 23 et 18%. On a egalement calcule
la frequence des parametres Biochimiques bas dans les
deux groupes en associant" diversement ies tests. Les
resultats obtenus ont montre que l'oestriol combine soit
avec la CAP ou avec la HCS sert d'indicateur beaucoup
plus precis dans le prediagnostic des complications foetales
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quc lorsqu'il est teste seul. Mais une association des trois
tests ne s'est pas revelee beaucoup plus significative que
celle de deux parametres.
En conclusion, on peut affirmer que les trois methodes
sont valables pour le prediagnostic des complications
foetales. Les tests d'oestiiol semblent etre d'un interet
plus grand a cet egaid que la CAP et la HCS. Les tests
d'oestriol urinaire devraient donc etre utilises commes
tests biochimiques primaires pour l'evaluation de Funite
foeto-placentaire. Une association des tests d'oestriol avec
CAP ou HCS a permis de detecter un plus grand nombre
de foetus nonsainsque les tests d'oestriol seul. L'association
de CAP et de HCS a ete au moins aussi instructive que les
tests d'oestriol seul et devrait etre appliquee de preference
comme test selectif pour depister les grossesses a insuffis-
ance placentaire eventuelle.
Mots-cles: cystine aminopeptidase, dyspnee foetale, excretion d'oestriol urinaire, grossesse a risque, somatomammo-
trophine chorionique humaine, test de la fonction placentaire.
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